Patton Fund Management Inc. Has $3.01 Million Stock Holdings in Gilead Sciences, Inc. $GILD

Patton Fund Management Inc. decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 63.8% during the 1st quarter, HoldingsChannel reports. The fund owned 21,594 shares of the biopharmaceutical company’s stock after selling 38,011 shares during the quarter. Patton Fund Management Inc.’s holdings in Gilead Sciences were worth $3,010,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of GILD. Strategic Investment Solutions Inc. IL acquired a new position in Gilead Sciences during the fourth quarter worth $25,000. Vermillion & White Wealth Management Group LLC increased its stake in Gilead Sciences by 71.4% in the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 85 shares during the last quarter. Quattro Advisors LLC acquired a new stake in Gilead Sciences in the 4th quarter valued at $26,000. Wealth Preservation Advisors LLC lifted its position in Gilead Sciences by 60.0% during the 4th quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 81 shares in the last quarter. Finally, Ares Financial Consulting LLC bought a new stake in Gilead Sciences during the 4th quarter worth about $28,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

GILD has been the subject of a number of recent research reports. Wall Street Zen downgraded shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Royal Bank Of Canada reaffirmed a “sector perform” rating on shares of Gilead Sciences in a research report on Monday, June 8th. Leerink Partners dropped their target price on Gilead Sciences from $148.00 to $146.00 in a report on Friday, May 8th. Jefferies Financial Group began coverage on Gilead Sciences in a research report on Tuesday, March 10th. They set a “buy” rating and a $180.00 price target for the company. Finally, Truist Financial restated a “buy” rating and issued a $157.00 price target (up from $155.00) on shares of Gilead Sciences in a research note on Friday, May 8th. Twenty-five analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $158.41.

Gilead Sciences Stock Down 0.0%

GILD stock opened at $127.86 on Monday. Gilead Sciences, Inc. has a 1-year low of $106.84 and a 1-year high of $157.29. The business’s 50 day simple moving average is $130.19 and its 200 day simple moving average is $134.38. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. The firm has a market capitalization of $158.75 billion, a PE ratio of 17.42 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The business had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. During the same quarter last year, the firm posted $1.81 EPS. The company’s quarterly revenue was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, research analysts anticipate that Gilead Sciences, Inc. will post -0.8 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be paid a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date is Monday, June 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently 44.69%.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $123.92, for a total value of $371,760.00. Following the transaction, the insider directly owned 124,234 shares of the company’s stock, valued at $15,395,077.28. This represents a 2.36% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $131.46, for a total transaction of $1,971,900.00. Following the sale, the chief executive officer owned 617,567 shares of the company’s stock, valued at $81,185,357.82. This trade represents a 2.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 68,000 shares of company stock worth $8,930,150. 0.30% of the stock is owned by insiders.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Trodelvy won first-line approval in the U.S. and Europe for metastatic triple-negative breast cancer, opening a larger treatment market and improving Gilead’s oncology growth profile. Gilead Sciences (GILD) Wins First Line Trodelvy Approval In The US And Europe
• Positive Sentiment: Cantor Fitzgerald reiterated an Overweight rating and $155 price target after positive HIV trial results, signaling continued analyst confidence in Gilead’s pipeline and longer-term earnings potential. Cantor Fitzgerald Reiterates Overweight Rating on Gilead Sciences (GILD) Following Positive HIV Trial Results
• Positive Sentiment: Merck’s FDA announcement that KEYTRUDA combinations can be used with Trodelvy in first-line advanced TNBC adds another validation point for Trodelvy’s role in frontline cancer care. FDA Approves KEYTRUDA and KEYTRUDA QLEX each with Trodelvy as First-Line Treatment of Advanced Triple-Negative Breast Cancer
• Neutral Sentiment: Recent coverage also noted Gilead’s stock had been drifting lower before the approval news, reflecting recent market weakness rather than a change in fundamentals. Gilead Sciences (GILD) Dips More Than Broader Market: What You Should Know

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.